biotech

biotech Articles

Proteostasis Therapeutics shares pulled back on Tuesday after the company announced that it would be conducting a secondary offering.
Mirati shares dropped on Monday after the company announced updated positive clinical data from its midstage study in non-small cell lung cancer.
Medical technology company Axonics Modulation Technologies is offering more than 6 million shares in an initial public offering valued up to more than $122 million.
Here is a preview of some of the world’s largest players in the health care sector reporting earnings this coming week.
Here are five biotech stocks that are rated Buy by the Jefferies analysts, are trading under the $10 level and could provide investors with some solid upside potential.
Clovis Oncology shares dropped on Friday after the company announced initial data from its Phase 2 clinical trial of Rubraca at the ESMO 2018 Congress.
Merrimack Pharmaceuticals shares dropped early on Friday after the company announced that it would be terminating its midstage SHERLOC study in patients with non-small cell lung cancer.
Genome editing company LogicBio Therapeutics expects to price more than 5 million shares for an initial public offering valued up to almost $93 million.
Proteostasis Therapeutics shares absolutely exploded on Thursday after the company announced positive preliminary results from its early-stage cystic fibrosis trial.
Endocyte shares were up sharply early Thursday after it was announced that the company would be acquired.
Synthetic biology company Twist Bioscience expects to price 5 million shares for an initial public offering valued up to more than $103 million.
Tetraphase Pharmaceuticals shares were up handily on Friday after the company announced the U.S. commercial launch of Xerava (eravacycline) for the treatment of complicated intra-abdominal infections.
Corium shares jumped on Friday after the company announced that it entered into a definitive merger agreement under which Gurnet Point Capital will acquire Corium.
Compugen shares pushed higher on Thursday after it was announced that Bristol-Myers Squibb will make a $12 million equity investment as part of its collaboration on a cancer trial.